Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BAL0891 |
| Synonyms | |
| Therapy Description |
BAL0891 inhibits both TTK (MPS1) and PLK1, which potentially leads to disrupted cell cycle progression and decreased tumor cell proliferation (Cancer Res (2022) 82 (12_Supplement): 5645). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BAL0891 | BAL-0891|BAL 0891 | MPS1 Inhibitor 27 PLK1 Inhibitor 18 | BAL0891 inhibits both TTK (MPS1) and PLK1, which potentially leads to disrupted cell cycle progression and decreased tumor cell proliferation (Cancer Res (2022) 82 (12_Supplement): 5645). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05768932 | Phase I | BAL0891 + Paclitaxel BAL0891 BAL0891 + Tislelizumab | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 1 |